You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Signal State Transition Software Development
SBC: Advanced Technologies, Inc Topic: 06FH1ATI's Phase II effort will consist of developing an open source Signal Control Program Environment (SCOPE). This SCOPE will incorporate either an open source traffic signal control program or a more refined version of the signal control logic ATI developed in our Phase I effort. ATI will develop SCOPE so that the Cooperative Intersection Collision Avoidance System (CICAS) and Adaptive Control Sys ...
SBIR Phase II 2011 Department of Transportation -
Microscopic Traffic Flow Simulation Models- An Open Source Approach
SBC: NEW GLOBAL SYSTEMS FOR INTELLIGENT TRANSPORTATION MANAGEMENT CORPORATION Topic: 081FH5PHASE II TECHNICAL OBJECTIVE The major objective of this Phase II proposal is to establish open source traffic simulation model and software, and to develop application programming interfaces to accommodate future traffic research needs. Objectives will be accomplished by building and demonstrating FOMM, an open source traffic simulation model and software. Furthermore, to accommodate future resea ...
SBIR Phase II 2011 Department of Transportation -
Novel HBV Therapeutic with Potential for Treatment of Drug-Resistant Infection
SBC: Pharmabridge, Inc. Topic: NIAIDDESCRIPTION (provided by applicant): This is a Phase II proposal to advance development of disubstituted tetrahydro-triazolo-pyrimidines (TTPs) as specific inhibitors of hepatitis B virus surface antigen (HBsAg) secretion in chronic infection. High serum levels of HBsAg (antigenemia) are believed to underlie immunotolerance toward the infection. Although they are clinically beneficial, the current ...
SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
Bioadhesive Membrane Construct to Augment Tendon Repair
SBC: KENSEY NASH CORPORATION Topic: NIAMSDESCRIPTION (provided by applicant): The frequency with which tendon ruptures occur is increasing due to medical advances that allow an aging population to remain physically active longer than previously possible. There is a great deal of controversy in the orthopaedic community regarding the most effective way to treat such injuries. While progress has been made in improving the method of fixatio ...
SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
Diagnostic Biomarkers for Radicular Pain
SBC: CYTONICS CORPORATION Topic: NIAMSDESCRIPTION (provided by applicant): This is a proposal to collect the necessary data for FDA regulatory approval of the Cytonics assay as a diagnostic tool to identify patients who will respond to steroid injection therapy for LBP due to radiculopathy. Low back pain (LBP) syndromes include spinal degenerative conditions with and without nerve root or cauda equina irritation. These syndromes repre ...
SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
Chemoprotectants for Head-Neck Therapeutics
SBC: REACTION BIOLOGY CORPORATION Topic: NCIDESCRIPTION (provided by applicant): Chemoprotectants for Head-Neck Therapeutics Oral mucositis occurs as a major dose-limiting and complicating side effect of chemotherapy, radiotherapy, or combined chemo/radiotherapy. It is considered the most significant complication of head and neck cancer therapy. Oral mucositis is accompanied by tremendous pain and can cause life threatening complications. D ...
SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
Bladder drug delivery using intravesical liposomes to treat overactive bladder
SBC: Lipella Pharmaceuticals Inc. Topic: NIDDKDESCRIPTION (provided by applicant): Lipella Pharmaceuticals Inc. has been funded by National Institutes of Health Small Business Innovation and Research (SBIR) grants to develop intravesical liposome nanoparticles to treat overactive bladder (OAB), interstitial cystitis/painful bladder syndrome (IC/PBS). The current SBIR will allow Lipella to expand its portfolio of patent applications regarding ...
SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
LOW COST MULTI-MODAL ARRAY BASED SMALL ANIMAL SCANNER
SBC: ULTRAVISION CORP Topic: NIBIBDESCRIPTION (provided by applicant): Low cost high frequency (15, 20 and 25 MHz), and high resolution medical imaging linear array transducers will be designed and constructed for commercial sale under the direction and design of the NIH Resource Center for Ultrasonic Transducer Technology at the University of Southern California. A newly developed high performance ultrasonic scanner, the UltraVis ...
SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
Improved Dehydration Process for Pharmaceutical Synthesis II
SBC: COMPACT MEMBRANE SYSTEMS, INC. Topic: NIGMSDESCRIPTION (provided by applicant): Compact Membrane Systems (CMS) proposes to develop a perfluoro membrane reactor technology that will provide a generally applicable tool for removing water and oxygen from pharmaceutical synthesis processes. This innovation aims to improve product quality and reduce manufacturing costs of pharmaceutical end products. Manufacturing cost reductions will be derive ...
SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
Tissue Factor Antagonists for ALI/ARDS
SBC: Altor BioScience, LLC Topic: NHLBIDESCRIPTION (provided by applicant): The pathogenesis of ALI/ARDS involves both procoagulant and inflammatory mechanisms. Extravascular fibrin deposition in the lung is a characteristic pathologic feature of ALI/ARDS and intra-alveolar thrombi develop inthe lungs of patients with ALI/ARDS. Tissue factor (TF), the trigger protein for activation of the extrinsic coagulation pathway, has a direct ro ...
SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health